Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority has awarded a $50 million option to the company's existing contract for the purchase of Cyfendus, or Anthrax vaccine adsorbed, adjuvanted.
Deliveries are set to start this year and finish by April, the company said.
This follows a previous $30 million contract modification to supply the vaccine this year. The project is backed by federal funds from the US Department of Health and Human Services, the company said.
Cyfendus was approved by the US Food and Drug Administration in July 2023 as a two-dose vaccine for post-exposure anthrax prevention in people 18 to 65 years old.
Shares of Emergent BioSolutions rose more than 4% in recent trading.
Price: 8.85, Change: +0.37, Percent Change: +4.36
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。